Media Room

Reliq Health Technologies Announces $4,000,000 Brokered Private Placement Co-led by Canaccord Genuity and Gravitas Securities

October 12, 2017

Reliq Health Technologies Announces $4,000,000 Brokered Private Placement Co-led by Canaccord Genuity and Gravitas Securities

VANCOUVER, British Columbia, Oct. 11, 2017 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT) (OTCQB:RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has entered into an engagement agreement with Canaccord Genuity Corp. and Gravitas Securities Inc. to act as co-lead agents on a commercially reasonable efforts basis in respect to a brokered private placement offering of up to 10,000,000 units (the “Units”) at a price of $0.40 per Unit for gross proceeds of up to $4,000,000 (the “Offering”) subject to completion of satisfactory due diligence. Each Unit will consist of one (1) common share in the capital of the Company (a “Share”) and one-half (1/2) transferable common share purchase warrant (each whole warrant, a “Warrant”), with each Warrant exercisable into one additional Share at a price of $0.60 for a period of two years from the date of closing. The Company intends to use the net proceeds of the offering for general working capital, product development and customer acquisition.

“We are delighted to have two of Canada’s leading independent brokerage firms support the Company,” said Dr. Lisa Crossley, CEO of Reliq.

The Company may pay fees and commissions on the Offering within the amount permitted by the policies of the TSX Venture Exchange (the “Exchange”). Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director

Back to the main Media Room page, or press the Back button on your browser.